Regulatory Exclusivity
Regulatory exclusivity is a statutory period after approval during which the regulator may not approve a competing application that relies on the innovator's data, running independently of any patent.
Exclusivity and patents are constantly conflated and behave differently. A patent is granted by the patent office, dates from filing, and is enforced by its holder in court. Exclusivity is granted by the medicines regulator, dates from approval, and binds the agency itself: for its term FDA will not approve, and sometimes will not accept, an application leaning on the innovator's safety and effectiveness data. A competitor remains free to run its own full programme, so exclusivity blocks the abbreviated route rather than competition as such.
The periods run in parallel rather than adding up. A new chemical entity earns five years, shortened where a generic challenges the patents; a supplement supported by new clinical investigations earns three years; an orphan indication earns seven; and paediatric studies add six months onto existing terms. Biological products run on a separate and longer clock, so whether a peptide sits above or below the forty amino acid boundary decides which schedule applies. These provisions are amended periodically and should be confirmed for a given product.
For forecasting, competition becomes possible only when the last barrier falls, and that is rarely the headline patent. Formulation patents, injector device patents, method-of-use patents and settlement agreements with defined entry dates all sit between an announced expiry and an actual launch.
The error worth flagging is reading an expiry as a price event: nothing happens on that date unless an applicant has completed the abbreviated route and is ready to ship, which for peptides means demonstrating impurity comparability. Grey-market sellers exploit the gap, describing material as available because a patent expired, which conflates two independent barriers and ignores that neither confers approval.